Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) announces the publication of its Annual Report for the year ended 31 December 2009. The filing date is 25 February 2010. The document serves to notify the SEC of the availability of the Annual Report and includes a detailed description of principal risks and uncertainties affecting the Group, as required by UK Disclosure and Transparency Rules.
Key Financial Metrics
The filing text references the publication of the Annual Report and the prior announcement of unaudited Preliminary Results on 4 February 2010 but does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity within this specific document. The following financial data points are explicitly mentioned:
- Trade Receivables: As of 31 December 2009, receivables due from the three largest US wholesalers totaled £867 million (compared to £1,067 million as of 31 December 2008).
- Product Sales: GSK had nine pharmaceutical products with over £500 million in annual global sales in 2009.
- Wholesale Concentration: Sales to the three largest wholesalers accounted for approximately 85% of the Group's US pharmaceutical sales in 2009.
Material Changes and Operational Impacts
While specific year-over-year financial growth rates are not listed in this text, the filing highlights significant operational and market changes impacting the 2009 results:
- Generic Competition: The US launch of generic products competing with major brands (Lamictal, Imitrex, Paxil CR, Requip, Wellbutrin XL, and Valtrex) had a significant impact on overall turnover and earnings for 2009.
- Legal Provisions: The Group made material provisions in 2009 related to legal proceedings and investigations, which reduced earnings.
- Pandemic Influenza: Deliveries of pandemic vaccines (H1N1) provided significant contributions to 2009 results. The Group expects 2010 sales levels to be roughly the same as 2009, though future contributions are uncertain.
- Receivables Reduction: Trade receivables from major US wholesalers decreased by approximately £200 million from the prior year.
Guidance, Outlook, Risks, and Contingencies
The filing contains extensive risk disclosures and limited forward-looking statements:
- Outlook: GSK expects pandemic influenza vaccine sales in 2010 to be roughly the same as in 2009. There is no assurance these sales will contribute significantly to results in 2011 or beyond.
- Strategic Priorities: The Group aims to grow a diversified business, deliver more products of value, and simplify its operating model.
- Principal Risks:
- R&D Failure: Risk that new products will not achieve commercial success or regulatory approval.
- Patent Loss: Threats from generic manufacturers and potential changes to intellectual property laws, particularly in the USA.
- Litigation: Exposure to product liability, anti-trust, and government investigations (including pricing and marketing probes in the USA).
- Regulatory & Pricing: Increasing pressure on healthcare budgets, price controls in major markets (Japan, Germany, EU), and potential US healthcare reform.
- Supply Chain: Risks of manufacturing interruptions and concentration of sales to a small number of US wholesalers.
- Economic Conditions: Global economic weakness and currency fluctuations (Sterling vs. USD, Euro, Yen).
- Contingencies: The Group is appealing a court decision regarding transfer pricing with Canadian Tax Authorities. It also faces potential environmental remediation costs and insurance coverage denials for product liability claims.
Investor Verification Checklist
- Verify the specific revenue, profit, and cash flow figures in the full Annual Report 2009 and the unaudited Preliminary Results announced on 4 February 2010, as they are not detailed in this Form 6-K.
- Assess the financial impact of the generic launch of key products (Lamictal, Valtrex, etc.) on 2009 margins and future revenue projections.
- Review the status of ongoing US government investigations into pricing and marketing practices and the potential for additional legal provisions.
- Monitor the outcome of the transfer pricing appeal with Canadian Tax Authorities and its effect on the effective tax rate.
- Evaluate the sustainability of pandemic influenza vaccine sales beyond 2010 given the volatility in government contracts.
- Confirm the creditworthiness of the three largest US wholesalers, which represent 85% of US pharmaceutical sales and hold a significant portion of trade receivables.